TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases.

TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases. Breast Cancer Res Treat. 2014 Aug; 146(3):557-66.

View in: PubMed

subject areas

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Benzamides
Brain Neoplasms
Camptothecin
Drug-Related Side Effects and Adverse Reactions
Female
Humans
Middle Aged
Neoplasm Staging
Receptor, ErbB-2
Survival Analysis
Triple Negative Breast Neoplasms
Vascular Endothelial Growth Factor A

authors with profiles

Rita Nanda